Key result
aP2 T-87C variant linked to lower triglycerides and reduced risk of CAD and diabetes.
Observational (n=7,899)
Answers are grounded in this paper and cite their sources.
Population genetic analysis demonstrates an aP2 promoter variant lowers diabetes and heart disease risk, indicating a protective metabolic effect.
Obesity and the associated pathologies including dyslipidemia, insulin resistance, type 2 diabetes, and cardiovascular disease constitute a major threat to global human health. Yet, the genetic factors that differentially predispose individuals to this cluster of pathologies are unclear. The fatty acid-binding protein aP2 is a cytoplasmic lipid chaperon expressed in adipocytes and macrophages. Mice with aP2 deficiency are partially resistant to obesity-induced insulin resistance and type 2 diabetes, have lower circulating triglycerides, and exhibit marked protection against atherosclerosis. Here, we demonstrate a functionally significant genetic variation at the aP2 locus in humans that results in decreased adipose tissue aP2 expression due to alteration of the CAAT box/enhancer-binding protein binding and reduced transcriptional activity of the aP2 promoter. In population genetic studies with 7,899 participants, individuals that carry this T-87C polymorphism had lower serum triglyceride levels and significantly reduced risk for coronary heart disease and type 2 diabetes compared with subjects homozygous for the WT allele. Taken together, our results indicate that reduction in aP2 activity in humans generate a metabolically favorable phenotype that is similar to aP2 deficiency in experimental models.
No takes yet. Share an insight, caveat, or question.
Tuncman et al. (2006) conducted an observational in Hypertriglyceridemia, type 2 diabetes, and cardiovascular disease (n=7,899). aP2 T-87C polymorphism vs. Homozygous for the wild-type (WT) allele was evaluated on Serum triglyceride levels and risk for coronary heart disease and type 2 diabetes. Among 7,899 participants, carriers of the aP2 T-87C polymorphism had lower serum triglycerides and significantly reduced risk for coronary heart disease and type 2 diabetes versus WT homozygotes.
Synapse has enriched 10 related papers. Consider them for comparative context: